Literature DB >> 17642513

Conformational flexibility in the flap domains of ligand-free HIV protease.

Holly Heaslet1, Robin Rosenfeld, Mike Giffin, Ying Chuan Lin, Karen Tam, Bruce E Torbett, John H Elder, Duncan E McRee, C David Stout.   

Abstract

The crystal structures of wild-type HIV protease (HIV PR) in the absence of substrate or inhibitor in two related crystal forms at 1.4 and 2.15 A resolution are reported. In one crystal form HIV PR adopts an 'open' conformation with a 7.7 A separation between the tips of the flaps in the homodimer. In the other crystal form the tips of the flaps are 'curled' towards the 80s loop, forming contacts across the local twofold axis. The 2.3 A resolution crystal structure of a sixfold mutant of HIV PR in the absence of substrate or inhibitor is also reported. The mutant HIV PR, which evolved in response to treatment with the potent inhibitor TL-3, contains six point mutations relative to the wild-type enzyme (L24I, M46I, F53L, L63P, V77I, V82A). In this structure the flaps also adopt a 'curled' conformation, but are separated and not in contact. Comparison of the apo structures to those with TL-3 bound demonstrates the extent of conformational change induced by inhibitor binding, which includes reorganization of the packing between twofold-related flaps. Further comparison with six other apo HIV PR structures reveals that the 'open' and 'curled' conformations define two distinct families in HIV PR. These conformational states include hinge motion of residues at either end of the flaps, opening and closing the entire beta-loop, and translational motion of the flap normal to the dimer twofold axis and relative to the 80s loop. The alternate conformations also entail changes in the beta-turn at the tip of the flap. These observations provide insight into the plasticity of the flap domains, the nature of their motions and their critical role in binding substrates and inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17642513     DOI: 10.1107/S0907444907029125

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  40 in total

1.  A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.

Authors:  Pia Rücker; Anselm H C Horn; Heike Meiselbach; Heinrich Sticht
Journal:  J Mol Model       Date:  2011-01-29       Impact factor: 1.810

2.  HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Annie Aniana; Jane M Sayer; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

3.  Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.

Authors:  Zhanglong Liu; Thomas M Casey; Mandy E Blackburn; Xi Huang; Linh Pham; Ian Mitchelle S de Vera; Jeffrey D Carter; Jamie L Kear-Scott; Angelo M Veloro; Luis Galiano; Gail E Fanucci
Journal:  Phys Chem Chem Phys       Date:  2016-02-17       Impact factor: 3.676

Review 4.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

5.  Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

Authors:  Fengling Liu; Andrey Y Kovalevsky; Yunfeng Tie; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2008-07-01       Impact factor: 5.469

6.  Atomistic simulations of the HIV-1 protease folding inhibition.

Authors:  Gennady Verkhivker; Guido Tiana; Carlo Camilloni; Davide Provasi; Ricardo A Broglia
Journal:  Biophys J       Date:  2008-03-28       Impact factor: 4.033

7.  Contribution of the 80s loop of HIV-1 protease to the multidrug-resistance mechanism: crystallographic study of MDR769 HIV-1 protease variants.

Authors:  Ravikiran S Yedidi; Georghe Proteasa; Jorge L Martinez; John F Vickrey; Philip D Martin; Zdzislaw Wawrzak; Zhigang Liu; Iulia A Kovari; Ladislau C Kovari
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-05-17

8.  Structure of the unbound form of HIV-1 subtype A protease: comparison with unbound forms of proteases from other HIV subtypes.

Authors:  Arthur H Robbins; Roxana M Coman; Edith Bracho-Sanchez; Marty A Fernandez; C Taylor Gilliland; Mi Li; Mavis Agbandje-McKenna; Alexander Wlodawer; Ben M Dunn; Robert McKenna
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-02-12

9.  Effects of PRE and POST therapy drug-pressure selected mutations on HIV-1 protease conformational sampling.

Authors:  Jeffrey D Carter; Estrella G Gonzales; Xi Huang; Adam N Smith; Ian Mitchelle S de Vera; Peter W D'Amore; James R Rocca; Maureen M Goodenow; Ben M Dunn; Gail E Fanucci
Journal:  FEBS Lett       Date:  2014-06-28       Impact factor: 4.124

10.  A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant.

Authors:  Michael J Giffin; Holly Heaslet; Ashraf Brik; Ying-Chuan Lin; Gabrielle Cauvi; Chi-Huey Wong; Duncan E McRee; John H Elder; C David Stout; Bruce E Torbett
Journal:  J Med Chem       Date:  2008-09-30       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.